Perrigo ROE 2010-2025 | PRGO
Current and historical return on equity (ROE) values for Perrigo (PRGO) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Perrigo ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2025-03-31 | $-0.18B | $4.36B | -4.02% |
| 2024-12-31 | $-0.17B | $4.32B | -3.78% |
| 2024-09-30 | $-0.16B | $4.57B | -3.43% |
| 2024-06-30 | $-0.12B | $4.55B | -2.65% |
| 2024-03-31 | $-0.01B | $4.69B | -0.17% |
| 2023-12-31 | $-0.01B | $4.77B | -0.27% |
| 2023-09-30 | $-0.01B | $4.74B | -0.10% |
| 2023-06-30 | $-0.07B | $4.85B | -1.42% |
| 2023-03-31 | $-0.14B | $4.83B | -2.95% |
| 2022-12-31 | $-0.14B | $4.84B | -2.89% |
| 2022-09-30 | $-0.11B | $4.60B | -2.15% |
| 2022-06-30 | $-0.12B | $4.85B | -2.29% |
| 2022-03-31 | $-0.11B | $5.11B | -2.08% |
| 2021-12-31 | $-0.07B | $5.15B | -1.29% |
| 2021-09-30 | $-0.25B | $5.18B | -4.64% |
| 2021-06-30 | $-0.35B | $5.51B | -6.21% |
| 2021-03-31 | $-0.23B | $5.56B | -4.03% |
| 2020-12-31 | $-0.16B | $5.66B | -2.81% |
| 2020-09-30 | $-0.01B | $5.82B | -0.12% |
| 2020-06-30 | $0.24B | $5.91B | 4.13% |
| 2020-03-31 | $0.19B | $5.79B | 3.26% |
| 2019-12-31 | $0.15B | $5.80B | 2.54% |
| 2019-09-30 | $0.25B | $5.76B | 4.32% |
| 2019-06-30 | $0.09B | $5.73B | 1.53% |
| 2019-03-31 | $0.11B | $5.70B | 1.99% |
| 2018-12-31 | $0.13B | $5.67B | 2.24% |
| 2018-09-30 | $0.12B | $5.66B | 2.04% |
| 2018-06-30 | $0.24B | $5.90B | 3.87% |
| 2018-03-31 | $0.13B | $6.21B | 2.11% |
| 2017-12-31 | $0.12B | $6.17B | 1.97% |
| 2017-09-30 | $-1.31B | $6.04B | -21.73% |
| 2017-06-30 | $-2.95B | $6.08B | -46.07% |
| 2017-03-31 | $-3.41B | $6.07B | -47.78% |
| 2016-12-31 | $-4.01B | $5.96B | -49.82% |
| 2016-09-30 | $-2.83B | $7.48B | -31.10% |
| 2016-06-30 | $-0.98B | $9.05B | -9.86% |
| 2016-03-31 | $-0.46B | $9.73B | -4.50% |
| 2015-12-31 | $0.04B | $10.11B | 0.42% |
| 2015-09-30 | $0.29B | $10.73B | 2.82% |
| 2015-06-30 | $0.12B | $10.66B | 1.26% |
| 2014-12-31 | $0.21B | $9.72B | 2.40% |
| 2014-09-30 | $0.06B | $8.72B | 0.67% |
| 2013-12-31 | $0.14B | $8.50B | 3.53% |
| 2013-09-30 | $0.33B | $2.47B | 14.40% |
| 2012-12-31 | $0.33B | $2.11B | 17.04% |
| 2012-09-30 | $0.32B | $1.97B | 17.83% |
| 2011-12-31 | $0.26B | $1.63B | 16.90% |
| 2011-09-30 | $0.25B | $1.54B | 17.15% |
| 2010-12-31 | $0.23B | $1.31B | 19.38% |
| 2010-09-30 | $0.20B | $1.21B | 18.14% |
| 2009-12-31 | $0.16B | $0.99B | 17.12% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $3.771B | $4.373B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $237.070B | 28.51 |
| Boston Scientific (BSX) | United States | $155.016B | 38.81 |
| Stryker (SYK) | United States | $151.431B | 31.66 |
| EssilorLuxottica (ESLOY) | France | $128.578B | 0.00 |
| Medtronic (MDT) | Ireland | $113.826B | 16.14 |
| Lonza Group Ag (LZAGY) | Switzerland | $51.396B | 0.00 |
| Haleon (HLN) | United Kingdom | $46.515B | 26.54 |
| ResMed (RMD) | United States | $37.575B | 28.22 |
| GE HealthCare Technologies (GEHC) | United States | $34.776B | 16.51 |
| Agilent Technologies (A) | United States | $34.216B | 22.31 |
| Terumo (TRUMY) | Japan | $26.620B | 34.58 |
| Koninklijke Philips (PHG) | Netherlands | $23.303B | 16.35 |
| Insulet (PODD) | United States | $21.112B | 82.87 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.610B | 11.95 |
| Baxter (BAX) | United States | $16.026B | 11.97 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.402B | 0.00 |
| Demant (WILYY) | Denmark | $9.110B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.748B | 23.48 |
| Lantheus Holdings (LNTH) | United States | $5.495B | 13.86 |
| Prestige Consumer Healthcare (PBH) | United States | $3.969B | 17.73 |
| Haemonetics (HAE) | United States | $3.667B | 16.70 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.393B | 28.20 |
| ICU Medical (ICUI) | United States | $3.321B | 24.49 |
| QuidelOrtho (QDEL) | United States | $2.015B | 13.86 |
| LeMaitre Vascular (LMAT) | United States | $1.891B | 42.27 |
| AtriCure (ATRC) | United States | $1.594B | 0.00 |
| Acuren (TIC) | United States | $1.327B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.269B | 12.88 |
| Green Thumb Industries (GTBIF) | United States | $1.158B | 26.05 |
| Neogen (NEOG) | United States | $1.103B | 14.11 |
| Phibro Animal Health (PAHC) | United States | $1.079B | 13.79 |
| BioLife Solutions (BLFS) | United States | $1.029B | 0.00 |
| InMode (INMD) | Israel | $0.937B | 9.45 |
| Kestra Medical Technologies (KMTS) | United States | $0.813B | 0.00 |
| Owens & Minor (OMI) | United States | $0.728B | 6.04 |
| CeriBell (CBLL) | United States | $0.671B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.639B | 0.00 |
| Evolus (EOLS) | United States | $0.593B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.544B | 0.00 |
| Valneva SE (VALN) | France | $0.487B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.443B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.424B | 0.00 |
| Surmodics (SRDX) | United States | $0.419B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.353B | 12.98 |
| Quanterix (QTRX) | United States | $0.334B | 0.00 |
| SNDL (SNDL) | Canada | $0.321B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.301B | 0.00 |
| Cerus (CERS) | United States | $0.283B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.277B | 23.33 |
| Sanuwave Health (SNWV) | United States | $0.276B | 0.00 |
| ZimVie (ZIMV) | United States | $0.274B | 12.46 |
| Cresco Labs (CRLBF) | United States | $0.258B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.256B | 0.00 |
| Brainsway (BWAY) | Israel | $0.245B | 64.88 |
| Aurora Cannabis (ACB) | Canada | $0.242B | 71.67 |
| Biote (BTMD) | United States | $0.225B | 6.34 |
| OraSure Technologies (OSUR) | United States | $0.225B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.208B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.195B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.190B | 0.00 |
| High Tide (HITI) | Canada | $0.187B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.186B | 15.18 |
| Organigram Global (OGI) | Canada | $0.177B | 0.00 |
| Omeros (OMER) | United States | $0.174B | 0.00 |
| Exagen (XGN) | United States | $0.149B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.141B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.133B | 16.35 |
| Jin Medical (ZJYL) | China | $0.099B | 0.00 |
| Fonar (FONR) | United States | $0.097B | 12.50 |
| TerrAscend (TSNDF) | Canada | $0.091B | 0.00 |
| Veru (VERU) | United States | $0.086B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.086B | 0.00 |
| Apyx Medical (APYX) | United States | $0.085B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.081B | 0.00 |
| Zynex (ZYXI) | United States | $0.080B | 0.00 |
| MacroGenics (MGNX) | United States | $0.079B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.076B | 0.00 |
| InterCure (INCR) | Israel | $0.067B | 0.00 |
| Agape ATP (ATPC) | $0.067B | 0.00 | |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.060B | 0.00 |
| Nephros (NEPH) | United States | $0.043B | 57.57 |
| Modular Medical (MODD) | United States | $0.038B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 12.75 |
| Safety Shot (SHOT) | United States | $0.033B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.028B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.018B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| Senestech (SNES) | United States | $0.011B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |